Big Pharma embraces HoloMonitor technology from PHI

October 5, 2015
Language flag

Upon completion of an extensive evaluation in early September one of the top pharmaceutical companies in the world has decided to acquire two HoloMonitor® instruments. The ordered configuration is an automated version of the HoloMonitor platform. The total retail price of the orders amounts to €60 000.

“The pharmaceutical industry uses what is known in the industry as high-content screening to select drug candidates from several 100 000 chemical substances. The orders from the leading Swiss pharma company are tremendously important for the company’s future and confirm the potential of HoloMonitor technology in high-content screening. Valuable feedback from the pharma industry will enable us to further improve our proprietary technology for more realistic drug characterization. Various reports value the global high-content screening market to 500-1 100 million USD annually”, said CEO Peter Egelberg.

More information regarding high-content screening…

MARKET REPORTS

Latest News

Directed issue registered at the Companies Registration Office

PHI Board of Directors’ proposal on a directed issue to Altium S.A. was resolved on the extraordinary general meeting on November 15, 2023. The directed issue has now been registered at the Swedish Companies Registration Office.

Bulletin from extraordinary general meeting in Phase Holographic Imaging PHI AB (publ) 15 november 2023

Phase Holographic Imaging PHI AB (publ) held an extraordinary general meeting on November 15, 2023. The following resolutions were passed at the meeting.
BioStock-PHI-CEO-reflects-on-the-company-momentum

BioStock: PHI’s CEO reflects on the Company’s momentum

BioStock reached out to PHI’s CEO, Patrik Eschricht, to delve into what latest developments have contributed to the heightened enthusiasm surrounding the company.
See All News